Related Experiment Video

Updated: Jul 16, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

107

The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of

Kieran F Docherty1, John J V McMurray1, Rafael Diaz2

  • 1British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Journal of Cardiac Failure
|September 8, 2023
PubMed

Insights

Omecamtiv mecarbil reduced worsening heart failure events or cardiovascular death in patients with heart failure and reduced ejection fraction. The drug showed similar benefits whether patients were enrolled as inpatients or outpatients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial investigated omecamtiv mecarbil for heart failure (HF) with reduced ejection fraction.
  • Patients with HF and reduced ejection fraction are at high risk for adverse cardiac events.

Purpose of the Study:

  • To evaluate the safety and efficacy of omecamtiv mecarbil based on patient randomization setting (inpatient vs. outpatient).
  • To compare outcomes in hospitalized versus outpatient participants in the GALACTIC-HF trial.

Main Methods:

  • Prespecified analysis of the GALACTIC-HF trial data.
  • Patients were randomized as inpatients or outpatients within one year of a worsening HF event.
  • Primary outcome: composite of worsening HF event or cardiovascular death.

Main Results:

  • Hospitalized patients (25% of 8232) had higher baseline N-terminal prohormone of B-type natriuretic peptide, lower blood pressure, more symptoms, and less frequent guideline-directed medical therapy compared to outpatients.
  • The primary outcome rate was higher in hospitalized patients (38.3/100 person-years) than outpatients (23.1/100 person-years).
  • Omecamtiv mecarbil demonstrated a similar risk reduction for the primary outcome in both hospitalized (HR 0.89) and outpatient settings (HR 0.94), with no significant interaction (P=.51).

Conclusions:

  • Patients hospitalized for HF with reduced ejection fraction experienced a higher rate of primary outcome events compared to outpatients.
  • Omecamtiv mecarbil effectively decreased the risk of primary outcome events irrespective of whether patients were initiated during hospitalization or as outpatients.
Abstract

Keywords:
Heart failureclinical trialmyotropeomecamtiv mecarbil

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.4K
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction08:35

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

Published on: August 17, 2022

2.4K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
22
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16